Curcumin compound reactivates Epstein–Barr virus, offering safer cancer therapy

A novel curcumin derivative, C210, activates the Epstein–Barr virus (EBV) lytic cycle without producing infectious virions by disrupting HSP90. This discovery opens avenues for safer EBV-positive cancer therapies.

XOMA to buy Kinnate; A pain biotech’s small IPO

Plus, news about Blueprint Medicines, Sosei Group and Poxel: XOMA to buy Kinnate Biopharma: The biotech royalty aggregator said it would pay $2.33 per share

February 17, 2024

Study finds mixed results for mobile health app in cardiac rehabilitation

Nearly one in three Americans wear a wearable device, like a smartwatch, to track their health and fitness.

September 27, 2023

How science journals are confronting the ‘existential’ question of politics this election

Donald Trump has changed the way scientists engage with presidential elections. After he was voted president in 2016, tens of thousands attended the March for

November 1, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.